Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (645)	3/8/2000 6:13:00 PM
From: Cube	Read Replies (1) \| Respond to of 1154

Nice little bit of help: JERSEY CITY, N.J., March 8 /PRNewswire/ -- The following is being issued by M.H. Meyerson & Co., Inc., a member of the National Association of Securities Dealers, CRD number 540: M.H. Meyerson & Co., Inc. (Nasdaq: MHMY) has raised its price target on Genome Therapeutics Corporation (Nasdaq: GENE) to $85 to reflect strong market demand. Further, we are maintaining our original earnings estimates of ($0.15) per share, or a net loss of $2.9 million, which corrects our previous report, for the fiscal year ending August 2000, and ($0.02) per share in the fiscal year ending August 2001. For more information contact Andrew H. Scott, Director of Research, or Jeffrey H. Berg, Ph.D., at 201-459-9440 or 800-422-4114; web site: mhmeyerson.com.